Literature DB >> 26331349

CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells.

Felipe Flores-Santibáñez1, Dominique Fernández1, Daniel Meza1, Gabriela Tejón1, Leonardo Vargas1, Lorena Varela-Nallar2, Sebastián Arredondo2, Victoria Guixé1, Mario Rosemblatt1,3,4, María Rosa Bono1, Daniela Sauma1.   

Abstract

The CD73 ectonucleotidase catalyses the hydrolysis of AMP to adenosine, an immunosuppressive molecule. Recent evidence has demonstrated that this ectonucleotidase is up-regulated in T helper type 17 cells when generated in the presence of transforming growth factor-β (TGF-β), and hence CD73 expression is related to the acquisition of immunosuppressive potential by these cells. TGF-β is also able to induce CD73 expression in CD8(+) T cells but the function of this ectonucleotidase in CD8(+) T cells is still unknown. Here, we show that Tc17 cells present high levels of the CD73 ectonucleotidase and produce adenosine; however, they do not suppress the proliferation of CD4(+) T cells. Interestingly, we report that adenosine signalling through A2A receptor favours interleukin-17 production and the expression of stem cell-associated transcription factors such as tcf-7 and lef-1 but restrains the acquisition of Tc1-related effector molecules such as interferon-γ and Granzyme B by Tc17 cells. Within the tumour microenvironment, CD73 is highly expressed in CD62L(+) CD127(+) CD8(+) T cells (memory T cells) and is down-regulated in GZMB(+) KLRG1(+) CD8(+) T cells (terminally differentiated T cells), demonstrating that CD73 is expressed in memory/naive cells and is down-regulated during differentiation. These data reveal a novel function of CD73 ectonucleotidase in arresting CD8(+) T-cell differentiation and support the idea that CD73-driven adenosine production by Tc17 cells may promote stem cell-like properties in Tc17 cells.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD73; Tc17; adenosine; cell differentiation; stem cell; tumour immunology

Mesh:

Substances:

Year:  2015        PMID: 26331349      PMCID: PMC4693903          DOI: 10.1111/imm.12529

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  44 in total

1.  A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.

Authors:  Magdalena Huber; Sylvia Heink; Henrike Grothe; Anna Guralnik; Katharina Reinhard; Karin Elflein; Thomas Hünig; Hans-Willi Mittrücker; Anne Brüstle; Thomas Kamradt; Michael Lohoff
Journal:  Eur J Immunol       Date:  2009-07       Impact factor: 5.532

2.  Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.

Authors:  Caglar Cekic; Joel Linden
Journal:  Cancer Res       Date:  2014-10-23       Impact factor: 12.701

3.  Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Rahul Roychoudhuri; David Clever; Alena Gros; Robert L Eil; Eric Tran; Ken-Ichi Hanada; Zhiya Yu; Douglas C Palmer; Sid P Kerkar; Ryan D Michalek; Trevor Upham; Anthony Leonardi; Nicolas Acquavella; Ena Wang; Francesco M Marincola; Luca Gattinoni; Pawel Muranski; Mark S Sundrud; Christopher A Klebanoff; Steven A Rosenberg; Douglas T Fearon; Nicholas P Restifo
Journal:  Cancer Res       Date:  2014-11-28       Impact factor: 12.701

Review 4.  Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  Memory T cell subsets, migration patterns, and tissue residence.

Authors:  Scott N Mueller; Thomas Gebhardt; Francis R Carbone; William R Heath
Journal:  Annu Rev Immunol       Date:  2012-12-03       Impact factor: 28.527

Review 6.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951

7.  Type 17 CD8+ T cells display enhanced antitumor immunity.

Authors:  Christian S Hinrichs; Andrew Kaiser; Chrystal M Paulos; Lydie Cassard; Luis Sanchez-Perez; Bianca Heemskerk; Claudia Wrzesinski; Zachary A Borman; Pawel Muranski; Nicholas P Restifo
Journal:  Blood       Date:  2009-05-26       Impact factor: 22.113

8.  Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.

Authors:  Shilpak Chatterjee; Krishnamurthy Thyagarajan; Pravin Kesarwani; Jin H Song; Myroslawa Soloshchenko; Jianing Fu; Stefanie R Bailey; Chenthamarkshan Vasu; Andrew S Kraft; Chrystal M Paulos; Xue-Zhong Yu; Shikhar Mehrotra
Journal:  Cancer Res       Date:  2014-09-09       Impact factor: 12.701

Review 9.  CD73 and adenosine generation in the creation of regulatory microenvironments.

Authors:  F S Regateiro; S P Cobbold; H Waldmann
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

10.  Extracellular adenosine regulates naive T cell development and peripheral maintenance.

Authors:  Caglar Cekic; Duygu Sag; Yuan-Ji Day; Joel Linden
Journal:  J Exp Med       Date:  2013-10-21       Impact factor: 14.307

View more
  13 in total

1.  CD73 expression identifies a subset of IgM+ antigen-experienced cells with memory attributes that is T cell and CD40 signalling dependent.

Authors:  Lucas D'Souza; Sneh Lata Gupta; Vineeta Bal; Satyajit Rath; Anna George
Journal:  Immunology       Date:  2017-08-23       Impact factor: 7.397

Review 2.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 3.  The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells.

Authors:  Meihong Da; Luxia Chen; Alexander Enk; Sabine Ring; Karsten Mahnke
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

4.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

Review 5.  Targeting ectonucleotidases to treat inflammation and halt cancer development in the gut.

Authors:  Maria Serena Longhi; Lili Feng; Simon C Robson
Journal:  Biochem Pharmacol       Date:  2021-01-15       Impact factor: 5.858

6.  Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+γδ1 Treg cells.

Authors:  Chao Ni; Qing-Qing Fang; Wu-Zhen Chen; Jin-Xing Jiang; Zhou Jiang; Jun Ye; Ting Zhang; Liu Yang; Fan-Bo Meng; Wen-Jie Xia; Miaochun Zhong; Jian Huang
Journal:  Signal Transduct Target Ther       Date:  2020-04-29

Review 7.  Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.

Authors:  Simone de Leve; Florian Wirsdörfer; Verena Jendrossek
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 8.  Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity.

Authors:  Marta Vuerich; Rasika P Harshe; Simon C Robson; Maria Serena Longhi
Journal:  Int J Mol Sci       Date:  2019-01-27       Impact factor: 5.923

9.  Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.

Authors:  Mariaelena Capone; Federica Fratangelo; Diana Giannarelli; Claudia Sorrentino; Roberta Turiello; Serena Zanotta; Domenico Galati; Gabriele Madonna; Marilena Tuffanelli; Luigi Scarpato; Antonio M Grimaldi; Assunta Esposito; Rosa Azzaro; Antonio Pinto; Ernesta Cavalcanti; Aldo Pinto; Silvana Morello; Paolo A Ascierto
Journal:  J Transl Med       Date:  2020-03-11       Impact factor: 5.531

10.  In Vitro-Generated Tc17 Cells Present a Memory Phenotype and Serve As a Reservoir of Tc1 Cells In Vivo.

Authors:  Felipe Flores-Santibáñez; Bárbara Cuadra; Dominique Fernández; Mariana V Rosemblatt; Sarah Núñez; Pablo Cruz; Felipe Gálvez-Cancino; J César Cárdenas; Alvaro Lladser; Mario Rosemblatt; María Rosa Bono; Daniela Sauma
Journal:  Front Immunol       Date:  2018-02-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.